Diagnósticos da América S.A. (BVMF:DASA3)

Market Cap	4.21B +85.2%
Revenue (ttm)	9.13B -27.4%
Net Income	-817.45M
EPS	-0.65
Shares Out	1.25B
PE Ratio	n/a
Forward PE	16.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,403,200
Open	3.400
Previous Close	3.260
Day's Range	3.230 - 3.490
52-Week Range	1.880 - 5.790
Beta	0.37
Analysts	Buy
Price Target	4.05 (+20.18%)
Earnings Date	Nov 5, 2026

About Diagnósticos da América

Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. The company operates through Hospitals and Oncology; Diagnostics - National Operations; and Diagnostics - International Operations segments. It also offers medical, property and vehicle rental, consultancy, and franchise contracting services. The company was formerly known as Laboratório Clínico Delboni Auriemo S.A. and changed its name to Diagnósticos da América S.A. in August 2000. Diagnósticos da América S.A. was f...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1961
• Employees: 26,255
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: DASA3

Financial Performance

In 2025, Diagnósticos da América's revenue was 11.17 billion, a decrease of -27.10% compared to the previous year's 15.32 billion. Losses were -1.15 billion, -3.92% less than in 2024.

Analyst Summary

According to 12 analysts, the average rating for DASA3 stock is "Buy." The 12-month stock price target is R$4.05, which is an increase of 20.18% from the latest price.

Price Target

R$4.05

(20.18% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error